Indivior PLC (LON:INDV) has earned a consensus rating of “Buy” from the seven brokerages that are presently covering the firm. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is GBX 345.71 ($4.21).

Several equities research analysts have commented on the stock. Deutsche Bank AG restated a “buy” rating and issued a GBX 290 ($3.53) price target on shares of Indivior PLC in a research note on Monday, August 1st. Stifel Nicolaus raised their price target on shares of Indivior PLC from GBX 310 ($3.78) to GBX 350 ($4.27) and gave the company a “buy” rating in a research note on Monday, July 11th. Jefferies Group raised their price target on shares of Indivior PLC from GBX 245 ($2.99) to GBX 285 ($3.47) and gave the company a “buy” rating in a research note on Wednesday, June 29th. Finally, Numis Securities Ltd reiterated a “buy” rating and set a GBX 340 ($4.14) price objective on shares of Indivior PLC in a research note on Friday, July 29th.

Indivior PLC (LON:INDV) traded down 2.29% during midday trading on Monday, reaching GBX 306.80. The company had a trading volume of 1,864,523 shares. Indivior PLC has a 52-week low of GBX 126.60 and a 52-week high of GBX 365.00. The company’s 50 day moving average is GBX 317.92 and its 200-day moving average is GBX 246.27. The company’s market capitalization is GBX 2.21 billion.

Indivior PLC Company Profile

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of prescription drugs that are based on buprenorphine for treatment of opioid dependence segment. The Company’s treatment and pipeline focuses on opioid use disorder, alcohol use disorder, overdose rescue and co-morbidities of addiction/schizophrenia.

Receive News & Stock Ratings for Indivior PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior PLC and related stocks with our FREE daily email newsletter.